カテゴリ： Allied Market Research, 世界, 医療/バイオ

僧帽弁疾患のグローバル市場（2022-2031）：僧帽弁修復、僧帽弁置換術、心臓再同期療法、僧帽弁治療

■ 英語タイトル：Mitral Valve Disease Market By Treatment Type (Mitral Valve Repair, Mitral Valve Replacement, Cardiac Resynchronization Therapy, Mitral Valve Therapeutics), By Indication (Mitral Valve Stenosis, Mitral Valve Prolapse, Mitral Valve Regurgitation), By End User (Hospitals, Ambulatory Surgical Centers, Others): Global Opportunity Analysis and Industry Forecast, 2022-2031

調査会社Allied Market Research社が発行したリサーチレポート（データ管理コード：ALD23SEP127）■ 発行会社/調査会社：Allied Market Research
■ 商品コード：ALD23SEP127
■ 発行日：2023年4月
■ 調査対象地域：グローバル
■ 産業分野：生命科学
■ ページ数：374
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後24時間以内）
■ 販売価格オプション（消費税別）
Online Only（1名閲覧、印刷不可）USD3,570 ⇒換算￥542,640見積依頼/購入/質問フォーム
Single User（1名閲覧）USD5,730 ⇒換算￥870,960見積依頼/購入/質問フォーム
Enterprise User（閲覧人数無制限）USD9,600 ⇒換算￥1,459,200見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Allied Market Research社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[僧帽弁疾患のグローバル市場（2022-2031）：僧帽弁修復、僧帽弁置換術、心臓再同期療法、僧帽弁治療]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

僧帽弁疾患市場は、2021年には24億4,783万ドルと評価され、2031年には56億9,253万ドルに達すると推定され、2022年から2031年までのCAGRは8.8%を示します。僧帽弁は、左心房と左心室の間の心臓の左側に位置する心臓の循環系に不可欠なコンポーネントです。僧帽弁は左心房から左心室への血液の流れを調節する役割を担っています。僧帽弁に病気や損傷があると、血液を効率的に送り出す心臓の能力に影響を及ぼすさまざまな問題が生じます。一般的な僧帽弁の状態には、僧帽弁狭窄症、僧帽弁逸脱症、僧帽弁閉鎖不全症などがあります。

例えば、弁が狭窄すると、左心房から左心室に流入する血液量が減少するため、左心房が拡大し、肺の圧力が上昇します。このような状態が続くと、息切れ、疲労感、胸痛などの症状が現れます。また、弁がうまく閉じないために血液が心房に逆流し、同様の症状を引き起こすケースもあります。いずれの場合も、治療には薬物療法や治療薬による症状の管理が行われますが、重症の場合は弁の修復や交換のための手術が必要になることもあります。僧帽弁閉鎖不全症の場合、心臓再同期療法が治療に用いられることもあります。

僧帽弁疾患市場の成長を促す主な要因は、僧帽弁疾患の有病率の増加です。僧帽弁閉鎖不全症、僧帽弁逸脱症、僧帽弁狭窄症などの僧帽弁疾患と診断される患者数が驚くほど増加しています。例えば、Journal of Clinical Medicine 2022によると、僧帽弁閉鎖不全症はヨーロッパで2番目に多く、米国では最も多い心臓弁膜症であり、75歳以上の人口における有病率は9.3%です。このように、僧帽弁狭窄症、僧帽弁逸脱症、僧帽弁閉鎖不全症などの僧帽弁疾患の有病率の増加は、治療薬、修復手術、置換手術、心臓同期療法などの様々な治療オプションに対する需要をエスカレートさせ、ひいては世界の僧帽弁疾患市場の成長に貢献しています。

加えて、技術の進歩は近年の市場成長を促進する上で重要な役割を果たしています。僧帽弁疾患の有病率が上昇するにつれて、治療結果の改善と回復時間の短縮を提供できるより優れた治療オプションに対する需要も同時に高まっています。この分野における最も重要な技術的進歩の一つは、経カテーテル僧帽弁置換術（TMVR）などの低侵襲技術の開発です。この技術では、鼠径部や胸部を小さく切開して、病気の弁を人工弁に置き換えます。これは、従来の開心術に比べ、回復時間の短縮や合併症のリスクの低減など、いくつかの利点があります。このように、医療分野では技術的に先進的な僧帽弁治療装置に対する大きな需要が市場の成長を促進しています。

さらに、老年人口の急増は、高齢者が僧帽弁疾患にかかりやすいという事実のため、世界中で僧帽弁疾患治療の需要を促進しています。さらに、加齢に伴い弁が損傷したり弱くなったりすることで、機能不全に陥りやすくなります。さらに、高血圧や肥満などの危険因子の増加は、僧帽弁疾患を発症するリスクを高める可能性があり、僧帽弁疾患市場の成長を促進すると予想されています。

しかし、僧帽弁の修復、置換、心臓同期化療法などの僧帽弁治療処置の費用は著しく高く、これが市場成長の障壁となっています。加えて、低開発国の人々の間では、利用可能な治療法に関する認識が低く、市場成長の妨げとなっています。さらに、僧帽弁治療製品の開発・上市に対する規制が厳しいことも、市場成長の妨げになっています。

それとは反対に、高度な医療サービスに対する需要の増加、僧帽弁治療薬や処置に対する認知度の向上、医療インフラへの政府投資は、予測期間中に市場拡大のための有益な機会を提供すると期待されています。アジア太平洋およびLAMEAの各国政府は、医療インフラの整備に多額の投資を行っており、医療サービスへのアクセスを増加させていることが、僧帽弁疾患市場の成長を顕著に促進しています。

世界の僧帽弁疾患市場は、治療タイプ、適応症、エンドユーザー、地域に区分されます。治療タイプ別では、僧帽弁修復、僧帽弁置換、心臓再同期療法（CRT）、僧帽弁治療薬に細分化されます。僧帽弁置換術のセグメントはさらに機械弁と生体弁（生体組織）に二分されます。一方、僧帽弁治療薬セグメントは、β遮断薬、利尿薬、抗凝固薬、その他に細分化されます。

適応症によって、市場は僧帽弁狭窄症、僧帽弁逸脱症、僧帽弁閉鎖不全症に細分化されます。さらに、僧帽弁閉鎖不全症分野は、一次性（変性）僧帽弁閉鎖不全症と二次性（機能性）僧帽弁閉鎖不全症に二分されます。エンドユーザー別では、市場は病院、外来手術センター、その他に分別されます。
地域別では、北米（米国、カナダ、メキシコ）、欧州（ドイツ、フランス、英国、イタリア、スペイン、その他の欧州地域）、アジア太平洋地域（日本、中国、オーストラリア、インド、韓国、その他のアジア太平洋地域）、LAMEA（ブラジル、南アフリカ、サウジアラビア、その他のLAMEA地域）で市場を分析します。
僧帽弁疾患市場で事業を展開する主要企業には、Valcare Medical、Affluent Medical、Abbott Laboratories、Corcym UK Limited、Edwards Lifesciences Corporation、Medtronic Plc.、ShockWave Medical, Inc.、Artivion, Inc.、Labcor Laboratorios Ltda、Braile Biomédica、Zydus Lifesciences Limited、Teva Pharmaceutical Industries Ltd.、Pfizer Inc.、Bayer AG、Novartis AGなどがあります。

ステークホルダーにとっての主なメリット
2021年から2031年までの僧帽弁疾患市場分析の市場セグメント、現在の動向、予測、ダイナミクスを定量的に分析し、僧帽弁疾患市場の有力な機会を特定します。
主要な促進要因、阻害要因、機会に関する情報とともに市場調査を提供します。
ポーターのファイブフォース分析により、バイヤーとサプライヤーの潜在力を明らかにし、ステークホルダーが利益重視のビジネス決定を行い、サプライヤーとバイヤーのネットワークを強化できるようにします。
僧帽弁疾患市場のセグメンテーションを詳細に分析することで、市場機会を見極めることができます。
各地域の主要国を世界市場への収益貢献度に応じてマッピングしています。
市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
僧帽弁疾患の地域別および世界市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析を含みます。

主な市場セグメント
治療タイプ別
僧帽弁修復術
僧帽弁置換術
製品タイプ
機械弁
生体弁
心臓再同期療法
僧帽弁治療薬
薬剤クラス
β遮断薬
利尿薬
抗凝固薬
その他

適応症別
僧帽弁狭窄症
僧帽弁逸脱症
僧帽弁閉鎖不全症
タイプ別
一次僧帽弁閉鎖不全症
二次性僧帽弁閉鎖不全症

エンドユーザー別
病院
外来手術センター
その他

地域別
北米
米国
カナダ
メキシコ
ヨーロッパ
ドイツ
フランス
イギリス
イタリア
スペイン
その他のヨーロッパ
アジア太平洋
日本
中国
インド
オーストラリア
韓国
その他のアジア太平洋地域
LAMEA
ブラジル
サウジアラビア
南アフリカ
その他の地域

主な市場プレイヤー
○ Bayer AG
○ Zydus Lifesciences Limited
○ Affluent Medical
○ Artivion, Inc.
○ Valcare Medical
○ Corcym UK Limited
○ Pfizer Inc.
○ Novartis AG
○ Teva Pharmaceutical Industries Ltd.
○ Medtronic plc
○ ShockWave Medical, Inc.
○ Braile Biomedica
○ Abbott Laboratories
○ Labcor Laboratorios Ltda
○ Edwards Lifesciences Corporation

第1章：イントロダクション
第2章：エグゼクティブサマリー
第3章：市場概要
第4章：僧帽弁疾患市場、治療タイプ別
第5章：僧帽弁疾患市場、疾患別
第6章：僧帽弁疾患市場、エンドユーザー別
第7章：僧帽弁疾患市場、地域別
第8章：競争状況
第9章：企業情報

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Bargaining power of suppliers
3.3.2. Bargaining power of buyers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increase in prevalence of mitral valve diseases
3.4.1.2. Increase in demand for minimally invasive procedures
3.4.1.3. Rise in geriatric population
3.4.1.4. Increase in product approvals for mitral valve diseases treatment

3.4.2. Restraints
3.4.2.1. High cost of mitral valve surgeries and risks associated with the procedure
3.4.2.2. Stringent regulations by the governing bodies

3.4.3. Opportunities
3.4.3.1. Technological advancements and introduction of novel mitral valves
3.4.3.2. Rise in healthcare expenditure

3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: MITRAL VALVE DISEASE MARKET, BY TREATMENT TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Mitral Valve Repair
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Mitral Valve Replacement
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.3.4. Mitral Valve Replacement Mitral Valve Disease Market by Product Type
4.4. Cardiac Resynchronization Therapy
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. Mitral Valve Therapeutics
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
4.5.4. Mitral Valve Therapeutics Mitral Valve Disease Market by Drug Class
CHAPTER 5: MITRAL VALVE DISEASE MARKET, BY INDICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Mitral Valve Stenosis
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Mitral Valve Prolapse
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Mitral Valve Regurgitation
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.4.4. Mitral Valve Regurgitation Mitral Valve Disease Market by Type
CHAPTER 6: MITRAL VALVE DISEASE MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospitals
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Ambulatory Surgical Centers
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Others
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: MITRAL VALVE DISEASE MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key trends and opportunities
7.2.2. Market size and forecast, by Treatment Type
7.2.3. Market size and forecast, by Indication
7.2.4. Market size and forecast, by End User
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Key market trends, growth factors and opportunities
7.2.5.1.2. Market size and forecast, by Treatment Type
7.2.5.1.3. Market size and forecast, by Indication
7.2.5.1.4. Market size and forecast, by End User
7.2.5.2. Canada
7.2.5.2.1. Key market trends, growth factors and opportunities
7.2.5.2.2. Market size and forecast, by Treatment Type
7.2.5.2.3. Market size and forecast, by Indication
7.2.5.2.4. Market size and forecast, by End User
7.2.5.3. Mexico
7.2.5.3.1. Key market trends, growth factors and opportunities
7.2.5.3.2. Market size and forecast, by Treatment Type
7.2.5.3.3. Market size and forecast, by Indication
7.2.5.3.4. Market size and forecast, by End User
7.3. Europe
7.3.1. Key trends and opportunities
7.3.2. Market size and forecast, by Treatment Type
7.3.3. Market size and forecast, by Indication
7.3.4. Market size and forecast, by End User
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Key market trends, growth factors and opportunities
7.3.5.1.2. Market size and forecast, by Treatment Type
7.3.5.1.3. Market size and forecast, by Indication
7.3.5.1.4. Market size and forecast, by End User
7.3.5.2. France
7.3.5.2.1. Key market trends, growth factors and opportunities
7.3.5.2.2. Market size and forecast, by Treatment Type
7.3.5.2.3. Market size and forecast, by Indication
7.3.5.2.4. Market size and forecast, by End User
7.3.5.3. UK
7.3.5.3.1. Key market trends, growth factors and opportunities
7.3.5.3.2. Market size and forecast, by Treatment Type
7.3.5.3.3. Market size and forecast, by Indication
7.3.5.3.4. Market size and forecast, by End User
7.3.5.4. Italy
7.3.5.4.1. Key market trends, growth factors and opportunities
7.3.5.4.2. Market size and forecast, by Treatment Type
7.3.5.4.3. Market size and forecast, by Indication
7.3.5.4.4. Market size and forecast, by End User
7.3.5.5. Spain
7.3.5.5.1. Key market trends, growth factors and opportunities
7.3.5.5.2. Market size and forecast, by Treatment Type
7.3.5.5.3. Market size and forecast, by Indication
7.3.5.5.4. Market size and forecast, by End User
7.3.5.6. Rest of Europe
7.3.5.6.1. Key market trends, growth factors and opportunities
7.3.5.6.2. Market size and forecast, by Treatment Type
7.3.5.6.3. Market size and forecast, by Indication
7.3.5.6.4. Market size and forecast, by End User
7.4. Asia-Pacific
7.4.1. Key trends and opportunities
7.4.2. Market size and forecast, by Treatment Type
7.4.3. Market size and forecast, by Indication
7.4.4. Market size and forecast, by End User
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Key market trends, growth factors and opportunities
7.4.5.1.2. Market size and forecast, by Treatment Type
7.4.5.1.3. Market size and forecast, by Indication
7.4.5.1.4. Market size and forecast, by End User
7.4.5.2. China
7.4.5.2.1. Key market trends, growth factors and opportunities
7.4.5.2.2. Market size and forecast, by Treatment Type
7.4.5.2.3. Market size and forecast, by Indication
7.4.5.2.4. Market size and forecast, by End User
7.4.5.3. India
7.4.5.3.1. Key market trends, growth factors and opportunities
7.4.5.3.2. Market size and forecast, by Treatment Type
7.4.5.3.3. Market size and forecast, by Indication
7.4.5.3.4. Market size and forecast, by End User
7.4.5.4. Australia
7.4.5.4.1. Key market trends, growth factors and opportunities
7.4.5.4.2. Market size and forecast, by Treatment Type
7.4.5.4.3. Market size and forecast, by Indication
7.4.5.4.4. Market size and forecast, by End User
7.4.5.5. South Korea
7.4.5.5.1. Key market trends, growth factors and opportunities
7.4.5.5.2. Market size and forecast, by Treatment Type
7.4.5.5.3. Market size and forecast, by Indication
7.4.5.5.4. Market size and forecast, by End User
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Key market trends, growth factors and opportunities
7.4.5.6.2. Market size and forecast, by Treatment Type
7.4.5.6.3. Market size and forecast, by Indication
7.4.5.6.4. Market size and forecast, by End User
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. Market size and forecast, by Treatment Type
7.5.3. Market size and forecast, by Indication
7.5.4. Market size and forecast, by End User
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Key market trends, growth factors and opportunities
7.5.5.1.2. Market size and forecast, by Treatment Type
7.5.5.1.3. Market size and forecast, by Indication
7.5.5.1.4. Market size and forecast, by End User
7.5.5.2. Saudi Arabia
7.5.5.2.1. Key market trends, growth factors and opportunities
7.5.5.2.2. Market size and forecast, by Treatment Type
7.5.5.2.3. Market size and forecast, by Indication
7.5.5.2.4. Market size and forecast, by End User
7.5.5.3. South Africa
7.5.5.3.1. Key market trends, growth factors and opportunities
7.5.5.3.2. Market size and forecast, by Treatment Type
7.5.5.3.3. Market size and forecast, by Indication
7.5.5.3.4. Market size and forecast, by End User
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Key market trends, growth factors and opportunities
7.5.5.4.2. Market size and forecast, by Treatment Type
7.5.5.4.3. Market size and forecast, by Indication
7.5.5.4.4. Market size and forecast, by End User
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2021
CHAPTER 9: COMPANY PROFILES
9.1. Abbott Laboratories
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.1.7. Key strategic moves and developments
9.2. Affluent Medical
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Key strategic moves and developments
9.3. Corcym UK Limited
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Key strategic moves and developments
9.4. Edwards Lifesciences Corporation
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.4.7. Key strategic moves and developments
9.5. Labcor Laboratorios Ltda
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.6. Medtronic plc
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.6.7. Key strategic moves and developments
9.7. ShockWave Medical, Inc.
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.7.7. Key strategic moves and developments
9.8. Valcare Medical
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.9. Artivion, Inc.
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.9.7. Key strategic moves and developments
9.10. Braile Biomedica
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.11. Zydus Lifesciences Limited
9.11.1. Company overview
9.11.2. Key Executives
9.11.3. Company snapshot
9.11.4. Operating business segments
9.11.5. Product portfolio
9.11.6. Business performance
9.12. Teva Pharmaceutical Industries Ltd.
9.12.1. Company overview
9.12.2. Key Executives
9.12.3. Company snapshot
9.12.4. Operating business segments
9.12.5. Product portfolio
9.12.6. Business performance
9.13. Pfizer Inc.
9.13.1. Company overview
9.13.2. Key Executives
9.13.3. Company snapshot
9.13.4. Operating business segments
9.13.5. Product portfolio
9.13.6. Business performance
9.14. Bayer AG
9.14.1. Company overview
9.14.2. Key Executives
9.14.3. Company snapshot
9.14.4. Operating business segments
9.14.5. Product portfolio
9.14.6. Business performance
9.15. Novartis AG
9.15.1. Company overview
9.15.2. Key Executives
9.15.3. Company snapshot
9.15.4. Operating business segments
9.15.5. Product portfolio
9.15.6. Business performance

LIST OF TABLES
TABLE 01. GLOBAL MITRAL VALVE DISEASE MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
TABLE 02. MITRAL VALVE DISEASE MARKET FOR MITRAL VALVE REPAIR, BY REGION, 2021-2031 ($MILLION)
TABLE 03. MITRAL VALVE DISEASE MARKET FOR MITRAL VALVE REPLACEMENT, BY REGION, 2021-2031 ($MILLION)
TABLE 04. GLOBAL MITRAL VALVE REPLACEMENT MITRAL VALVE DISEASE MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
TABLE 05. MITRAL VALVE DISEASE MARKET FOR CARDIAC RESYNCHRONIZATION THERAPY, BY REGION, 2021-2031 ($MILLION)
TABLE 06. MITRAL VALVE DISEASE MARKET FOR MITRAL VALVE THERAPEUTICS, BY REGION, 2021-2031 ($MILLION)
TABLE 07. GLOBAL MITRAL VALVE THERAPEUTICS MITRAL VALVE DISEASE MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 08. GLOBAL MITRAL VALVE DISEASE MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 09. MITRAL VALVE DISEASE MARKET FOR MITRAL VALVE STENOSIS, BY REGION, 2021-2031 ($MILLION)
TABLE 10. MITRAL VALVE DISEASE MARKET FOR MITRAL VALVE PROLAPSE, BY REGION, 2021-2031 ($MILLION)
TABLE 11. MITRAL VALVE DISEASE MARKET FOR MITRAL VALVE REGURGITATION, BY REGION, 2021-2031 ($MILLION)
TABLE 12. GLOBAL MITRAL VALVE REGURGITATION MITRAL VALVE DISEASE MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 13. GLOBAL MITRAL VALVE DISEASE MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 14. MITRAL VALVE DISEASE MARKET FOR HOSPITALS, BY REGION, 2021-2031 ($MILLION)
TABLE 15. MITRAL VALVE DISEASE MARKET FOR AMBULATORY SURGICAL CENTERS, BY REGION, 2021-2031 ($MILLION)
TABLE 16. MITRAL VALVE DISEASE MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 17. MITRAL VALVE DISEASE MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 18. NORTH AMERICA MITRAL VALVE DISEASE MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
TABLE 19. NORTH AMERICA MITRAL VALVE DISEASE MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 20. NORTH AMERICA MITRAL VALVE DISEASE MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 21. NORTH AMERICA MITRAL VALVE DISEASE MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 22. U.S. MITRAL VALVE DISEASE MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
TABLE 23. U.S. MITRAL VALVE DISEASE MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 24. U.S. MITRAL VALVE DISEASE MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 25. CANADA MITRAL VALVE DISEASE MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
TABLE 26. CANADA MITRAL VALVE DISEASE MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 27. CANADA MITRAL VALVE DISEASE MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 28. MEXICO MITRAL VALVE DISEASE MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
TABLE 29. MEXICO MITRAL VALVE DISEASE MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 30. MEXICO MITRAL VALVE DISEASE MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 31. EUROPE MITRAL VALVE DISEASE MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
TABLE 32. EUROPE MITRAL VALVE DISEASE MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 33. EUROPE MITRAL VALVE DISEASE MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 34. EUROPE MITRAL VALVE DISEASE MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 35. GERMANY MITRAL VALVE DISEASE MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
TABLE 36. GERMANY MITRAL VALVE DISEASE MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 37. GERMANY MITRAL VALVE DISEASE MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 38. FRANCE MITRAL VALVE DISEASE MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
TABLE 39. FRANCE MITRAL VALVE DISEASE MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 40. FRANCE MITRAL VALVE DISEASE MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 41. UK MITRAL VALVE DISEASE MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
TABLE 42. UK MITRAL VALVE DISEASE MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 43. UK MITRAL VALVE DISEASE MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 44. ITALY MITRAL VALVE DISEASE MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
TABLE 45. ITALY MITRAL VALVE DISEASE MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 46. ITALY MITRAL VALVE DISEASE MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 47. SPAIN MITRAL VALVE DISEASE MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
TABLE 48. SPAIN MITRAL VALVE DISEASE MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 49. SPAIN MITRAL VALVE DISEASE MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 50. REST OF EUROPE MITRAL VALVE DISEASE MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
TABLE 51. REST OF EUROPE MITRAL VALVE DISEASE MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 52. REST OF EUROPE MITRAL VALVE DISEASE MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 53. ASIA-PACIFIC MITRAL VALVE DISEASE MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
TABLE 54. ASIA-PACIFIC MITRAL VALVE DISEASE MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 55. ASIA-PACIFIC MITRAL VALVE DISEASE MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 56. ASIA-PACIFIC MITRAL VALVE DISEASE MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 57. JAPAN MITRAL VALVE DISEASE MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
TABLE 58. JAPAN MITRAL VALVE DISEASE MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 59. JAPAN MITRAL VALVE DISEASE MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 60. CHINA MITRAL VALVE DISEASE MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
TABLE 61. CHINA MITRAL VALVE DISEASE MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 62. CHINA MITRAL VALVE DISEASE MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 63. INDIA MITRAL VALVE DISEASE MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
TABLE 64. INDIA MITRAL VALVE DISEASE MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 65. INDIA MITRAL VALVE DISEASE MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 66. AUSTRALIA MITRAL VALVE DISEASE MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
TABLE 67. AUSTRALIA MITRAL VALVE DISEASE MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 68. AUSTRALIA MITRAL VALVE DISEASE MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 69. SOUTH KOREA MITRAL VALVE DISEASE MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
TABLE 70. SOUTH KOREA MITRAL VALVE DISEASE MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 71. SOUTH KOREA MITRAL VALVE DISEASE MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 72. REST OF ASIA-PACIFIC MITRAL VALVE DISEASE MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
TABLE 73. REST OF ASIA-PACIFIC MITRAL VALVE DISEASE MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 74. REST OF ASIA-PACIFIC MITRAL VALVE DISEASE MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 75. LAMEA MITRAL VALVE DISEASE MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
TABLE 76. LAMEA MITRAL VALVE DISEASE MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 77. LAMEA MITRAL VALVE DISEASE MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 78. LAMEA MITRAL VALVE DISEASE MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 79. BRAZIL MITRAL VALVE DISEASE MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
TABLE 80. BRAZIL MITRAL VALVE DISEASE MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 81. BRAZIL MITRAL VALVE DISEASE MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 82. SAUDI ARABIA MITRAL VALVE DISEASE MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
TABLE 83. SAUDI ARABIA MITRAL VALVE DISEASE MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 84. SAUDI ARABIA MITRAL VALVE DISEASE MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 85. SOUTH AFRICA MITRAL VALVE DISEASE MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
TABLE 86. SOUTH AFRICA MITRAL VALVE DISEASE MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 87. SOUTH AFRICA MITRAL VALVE DISEASE MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 88. REST OF LAMEA MITRAL VALVE DISEASE MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
TABLE 89. REST OF LAMEA MITRAL VALVE DISEASE MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 90. REST OF LAMEA MITRAL VALVE DISEASE MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 91. ABBOTT LABORATORIES: KEY EXECUTIVES
TABLE 92. ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 93. ABBOTT LABORATORIES: PRODUCT SEGMENTS
TABLE 94. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 95. ABBOTT LABORATORIES: KEY STRATERGIES
TABLE 96. AFFLUENT MEDICAL: KEY EXECUTIVES
TABLE 97. AFFLUENT MEDICAL: COMPANY SNAPSHOT
TABLE 98. AFFLUENT MEDICAL: PRODUCT SEGMENTS
TABLE 99. AFFLUENT MEDICAL: PRODUCT PORTFOLIO
TABLE 100. AFFLUENT MEDICAL: KEY STRATERGIES
TABLE 101. CORCYM UK LIMITED: KEY EXECUTIVES
TABLE 102. CORCYM UK LIMITED: COMPANY SNAPSHOT
TABLE 103. CORCYM UK LIMITED: PRODUCT SEGMENTS
TABLE 104. CORCYM UK LIMITED: PRODUCT PORTFOLIO
TABLE 105. CORCYM UK LIMITED: KEY STRATERGIES
TABLE 106. EDWARDS LIFESCIENCES CORPORATION: KEY EXECUTIVES
TABLE 107. EDWARDS LIFESCIENCES CORPORATION: COMPANY SNAPSHOT
TABLE 108. EDWARDS LIFESCIENCES CORPORATION: PRODUCT SEGMENTS
TABLE 109. EDWARDS LIFESCIENCES CORPORATION: PRODUCT PORTFOLIO
TABLE 110. EDWARDS LIFESCIENCES CORPORATION: KEY STRATERGIES
TABLE 111. LABCOR LABORATORIOS LTDA: KEY EXECUTIVES
TABLE 112. LABCOR LABORATORIOS LTDA: COMPANY SNAPSHOT
TABLE 113. LABCOR LABORATORIOS LTDA: PRODUCT SEGMENTS
TABLE 114. LABCOR LABORATORIOS LTDA: PRODUCT PORTFOLIO
TABLE 115. MEDTRONIC PLC: KEY EXECUTIVES
TABLE 116. MEDTRONIC PLC: COMPANY SNAPSHOT
TABLE 117. MEDTRONIC PLC: PRODUCT SEGMENTS
TABLE 118. MEDTRONIC PLC: PRODUCT PORTFOLIO
TABLE 119. MEDTRONIC PLC: KEY STRATERGIES
TABLE 120. SHOCKWAVE MEDICAL, INC.: KEY EXECUTIVES
TABLE 121. SHOCKWAVE MEDICAL, INC.: COMPANY SNAPSHOT
TABLE 122. SHOCKWAVE MEDICAL, INC.: PRODUCT SEGMENTS
TABLE 123. SHOCKWAVE MEDICAL, INC.: PRODUCT PORTFOLIO
TABLE 124. SHOCKWAVE MEDICAL, INC.: KEY STRATERGIES
TABLE 125. VALCARE MEDICAL: KEY EXECUTIVES
TABLE 126. VALCARE MEDICAL: COMPANY SNAPSHOT
TABLE 127. VALCARE MEDICAL: PRODUCT SEGMENTS
TABLE 128. VALCARE MEDICAL: PRODUCT PORTFOLIO
TABLE 129. ARTIVION, INC.: KEY EXECUTIVES
TABLE 130. ARTIVION, INC.: COMPANY SNAPSHOT
TABLE 131. ARTIVION, INC.: PRODUCT SEGMENTS
TABLE 132. ARTIVION, INC.: PRODUCT PORTFOLIO
TABLE 133. ARTIVION, INC.: KEY STRATERGIES
TABLE 134. BRAILE BIOMEDICA: KEY EXECUTIVES
TABLE 135. BRAILE BIOMEDICA: COMPANY SNAPSHOT
TABLE 136. BRAILE BIOMEDICA: PRODUCT SEGMENTS
TABLE 137. BRAILE BIOMEDICA: PRODUCT PORTFOLIO
TABLE 138. ZYDUS LIFESCIENCES LIMITED: KEY EXECUTIVES
TABLE 139. ZYDUS LIFESCIENCES LIMITED: COMPANY SNAPSHOT
TABLE 140. ZYDUS LIFESCIENCES LIMITED: PRODUCT SEGMENTS
TABLE 141. ZYDUS LIFESCIENCES LIMITED: PRODUCT PORTFOLIO
TABLE 142. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
TABLE 143. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 144. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
TABLE 145. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 146. PFIZER INC.: KEY EXECUTIVES
TABLE 147. PFIZER INC.: COMPANY SNAPSHOT
TABLE 148. PFIZER INC.: PRODUCT SEGMENTS
TABLE 149. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 150. BAYER AG: KEY EXECUTIVES
TABLE 151. BAYER AG: COMPANY SNAPSHOT
TABLE 152. BAYER AG: PRODUCT SEGMENTS
TABLE 153. BAYER AG: PRODUCT PORTFOLIO
TABLE 154. NOVARTIS AG: KEY EXECUTIVES
TABLE 155. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 156. NOVARTIS AG: PRODUCT SEGMENTS
TABLE 157. NOVARTIS AG: PRODUCT PORTFOLIO

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 化石燃料エネルギーのグローバル市場（2022-2031）：石炭、石油、天然ガス
  • 終夜眠ポリグラフ検査（PSG）システムのグローバル市場（2022-2031）：12チャネル以下PSGシステム、24チャネル以下PSGシステム、32チャネル以下PSGシステム、32チャネル以上PSGシステム
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(ALD23SEP127 )"僧帽弁疾患のグローバル市場（2022-2031）：僧帽弁修復、僧帽弁置換術、心臓再同期療法、僧帽弁治療" (英文：Mitral Valve Disease Market By Treatment Type (Mitral Valve Repair, Mitral Valve Replacement, Cardiac Resynchronization Therapy, Mitral Valve Therapeutics), By Indication (Mitral Valve Stenosis, Mitral Valve Prolapse, Mitral Valve Regurgitation), By End User (Hospitals, Ambulatory Surgical Centers, Others): Global Opportunity Analysis and Industry Forecast, 2022-2031)はAllied Market Research社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。